Detailed Information on Publication Record
2023
Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry
TABORSKY, Milos, Tomas SKALA, Marian FEDORCO, Vlastimil DOUPAL, Ingrid SOVOVA et. al.Basic information
Original name
Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry
Authors
TABORSKY, Milos (203 Czech Republic), Tomas SKALA (203 Czech Republic, guarantor), Marian FEDORCO (203 Czech Republic), Vlastimil DOUPAL (203 Czech Republic), Ingrid SOVOVA (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Monika BEZDEKOVA (203 Czech Republic), Marek VICHA (203 Czech Republic), Josef DANEK (203 Czech Republic) and Josef KAUTZNER (203 Czech Republic)
Edition
Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30230 Other clinical medicine subjects
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 0.900 in 2022
RIV identification code
RIV/00216224:14110/23:00129947
Organization unit
Faculty of Medicine
UT WoS
000733638200001
Keywords in English
implantable cardioverter-defibrillator; heart failure; primary prevention; time to shock; sppropriate shock; mortality
Tags
International impact, Reviewed
Změněno: 26/1/2024 09:48, Mgr. Tereza Miškechová
Abstract
V originále
Background. Clinical parameters linked to a low benefit of ICD implantation and increased mortality risks are needed for an individualized assessment of potential benefits and risks of ICD implantation. Methods. Analysis of a prospective registry of all patients hospitalized from 2009 to 2019 in a single centre for a first Results. A total of 2,681 patients were included in the registry. Until the end of follow-up (38.4 +/- 29.1 months), 682 (25.4%) patients died. The one-year mortality in all patients, the one-year CV mortality, the three-year mortality in all patients, and the three-year CV mortality were 7.8%, 5.7%, 20.6%, and 14.8%, respectively. There was a statistically significant difference when the subgroups were compared according to the type of cardiomyopathy. No significant difference was found between primary and secondary prevention and between the types of devices. Male gender, age >= 75 years, diabetes mellitus, and atrial fibrillation were associated with a significantly increased mortality risk. Conclusion. In an analysis of a long-term follow-up of 2,681 ICD patients, we found no mortality difference between patients with ischemic or non-ischemic cardiomyopathy and in the device type. A higher mortality risk was found in men, patients older than 75 years, diabetics, and those with atrial fibrillation.